Soundscape phenology: The effect of environmental and climatic factors on birds and insects in a subtropical woodland.

Climate change and biodiversity loss are significant global environmental issues. However, to understand their impacts we need to know how fauna respond to environmental and climatic variation over time. In this study, remote sensing techniques (satellite imagery and passive acoustic recorders) were used to investigate the variation in biophony over different timescales, ranging from one day to one year, in a sub-tropical woodland in eastern Australia. The prominent sources of biophony were birds at dawn and during the day, nocturnal insects at dusk and during the night, and diurnal birds and insects (mainly cicadas) over the summer period of December, January, and February. While different environmental factors were found to be key drivers of phenological response in different faunal groups, temperature, humidity and the interactions between temperature, humidity, moon illumination and vegetation greenness were most important factors overall. Using observed temperatures relative to the historical mean for each day of the year, we evaluated the impact of higher-than-average temperatures on calling activity. We found that nocturnal insects call less frequently on days when the temperature was hotter than average in winter months (June, July, and August), and birds call less frequently in hot spring days (September, October, and November) meaning these groups can be susceptible to temperature increase as consequence, for example, of climate change. This study demonstrates how animal calling behaviour is affected by different environmental variables over different temporal scales. This study also demonstrates the utility of remote sensing techniques for assessing the impacts of climate change on biodiversity. It is highly recommended that monitoring schemes and impact assessments account for phenological changes and environmental variability, as these are complex and important processes shaping animal communities.

Histopathology of Prostate Cancer and its Precursors.

Starting in the mid-1970s, we formed a group of pathologists with a major interest in uropathology. Originally, it included 2 (R.M. and M.S.). In the years the followed, the group was enlarged to include 4 more people, 2 in the mid- and late-1980s (A.L.B. and L.C.) and another in the mid-1990s (R.Ma.); a sixth (A.C.) joined the group ∼5 years ago. Two have reached the retirement age (R.M. and M.S.), while others are in the process of joining the group to replace them. A fruitful collaboration spanned for ∼45 years. This contribution is based on a series of personal recollections of the successive changes in the interpretation of prostate cancer and its precursors, starting in the mid-1970s. Here we have retraced our involvement steps, sharing issues related to them with a junior uropathologist (A.C.).

Spectrum of incipient (or precursor) lesions in the mucosa of the seminal vesicles.

The seminal vesicle (SV) mucosa can show epithelial and stromal tumors. The epithelial tumors include both cystadenoma and carcinomas, adenocarcinoma being the most common. Squamous carcinoma may arise in the SV (1). Rarely mixed epithelial and stromal tumors (MESTs) can occur. Incipient lesions, i.e., primary precursor or preinvasive lesions giving rise to such tumors in the mucosa of the SVs, have been observed in anecdotal cases.

Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients.

Caveolin-1 (Cav-1) plays a key role in various neoplastic diseases and is upregulated in different cancers, including pancreatic ductal adenocarcinoma (PDAC). Furthermore, Cav-1 is critical for the uptake of albumin as well as nab-paclitaxel in PDAC cells. Here, we investigated the prognostic impact of Cav-1 expression in a cohort of 39 metastatic PDAC patients treated with different first-line chemotherapy regimens. We also assessed the predictive value of Cav-1 in patients treated with gemcitabine and nab-paclitaxel. Cav-1 expression was evaluated by immunohistochemistry staining in neoplastic and stromal cells, using metastatic sites or primary tumor tissue specimens. Higher levels of Cav-1 expression were associated with significantly worse overall survival (OS) and progression-free survival (PFS). No differences in OS were found between patients treated with gemcitabine + nab-paclitaxel vs. other chemotherapy options. Multivariate analysis for OS and PFS confirmed the independent prognostic role of Cav-1 expression. Our study evidenced a negative prognostic role of Cav-1 in patients affected by metastatic/locally advanced unresectable PDAC. Moreover, Cav-1 expression seems not to predict different response rates to different types of first-line treatment. Future prospective trials will be necessary to confirm the prognostic role of Cav-1 and explore Cav-1 specific inhibitors as a therapeutic option for advanced PDAC patients.

Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation.

The 2021 novelties in prognostic and therapeutic tissue markers in patients with prostate cancer (PCa) can be subdivided into two major groups. The first group is related to prognostic markers based on morphological and immunohistochemical evaluations. The novelties in this group can then be subdivided into two subgroups, one involving morphologic evaluation only, i.e., PCa grading, and the other involving both morphologic and immunohistochemical evaluations, i.e., aggressive variant PCa (AVPCa). Grading concerns androgen-dependent PCa, while AVPCa represents a late phase in its natural history, when it becomes androgen-independent. The novelties of the other major group are related to molecular markers predicting significant disease or response to therapy. This group mainly includes novelties in the molecular evaluation of PCa in tissue material and liquid biopsies.